A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
NCT03201718 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 505
Last updated 2020-10-08
Summary
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.
Conditions
- Hepatitis C Virus (HCV)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-17
- Primary Completion
- 2019-10-11
- Completion
- 2019-10-11
Countries
- South Korea
Study Locations
More Related Trials
-
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
NCT02441283 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
NCT02402452 ·Status: COMPLETED ·Phase: PHASE1
-
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
NCT01773070 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
NCT04695769 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
NCT01949168 ·Status: UNKNOWN ·Phase: PHASE2
-
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
NCT02461745 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
NCT02219503 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
NCT02798315 ·Status: COMPLETED
-
A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection
NCT02498015 ·Status: COMPLETED ·Phase: PHASE4
-
MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV
NCT03003338 ·Status: TERMINATED ·Phase: PHASE4
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
NCT00718172 ·Status: COMPLETED ·Phase: PHASE1
-
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
NCT02640547 ·Status: COMPLETED
-
Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet
NCT02589457 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
NCT02185794 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
NCT01371578 ·Status: COMPLETED ·Phase: PHASE2
-
36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
NCT01683786 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C
NCT02639585 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
NCT00047814 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
NCT00332176 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
NCT01511432 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot HCV Direct Acting Antiviral Therapy and Metabolism
NCT02734173 ·Status: COMPLETED ·Phase: PHASE4
-
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
NCT00301509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
NCT02615145 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
NCT02442284 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
NCT01701401 ·Status: COMPLETED ·Phase: PHASE3